10

Mar2016

CADTH Call for Patient Input for Etanercept SEB

The Canadian Agency for Drugs and Technologies in Health (CADTH) posted a call for patient input on March 9, 2016 for etanercept - the subsequent entry biologic (SEB) version of Amgen’s ENBREL™. For those interested in providing patient input, please complete the CDR Patient Input Submission. According to the ... Read More

26

Feb2016

Update on Procedures for the CADTH Common Drug Review and pan-Canadian Oncology Drug Review: Mandatory Disclosure of a Submitted Drug Price

Revised Procedures for CDR and pCODR For all drug applications filed for review through either the Common Drug Review (CDR) or pan-Canadian Oncology Drug Review (pCODR) process on or after April 1, 2016, CADTH will no longer accept confidential submitted prices. The submitted price will be disclosed in all applicable CDR ... Read More

06

Oct2015

Expanding the CADTH Drug Review Process to Receive Patient Input Submissions from Individual Patients and Caregivers

Based on stakeholder feedback received in May 2015, CADTH has announced that in the limited instances where no Canadian patient group exists, individual patient and caregiver input will now be accepted for the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) programs, effective immediately. Please note that for ... Read More